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Summary	8	
Strengthening	governance	is	an	essential	strategy	to	tackling	antimicrobial	resistance	(AMR)	at	all	9	
levels;	global,	national,	regional	and	local.	To	date,	no	systematic	approach	to	governance	of	AMR	10	
national	action	plans	(NAPs)	exists.	To	address	this,	we	aimed	to	develop	the	first	governance	11	
framework	to	offer	guidance	for	both	the	development	and	assessment	of	AMR	national	action	plans	12	
(NAPs).	We	reviewed	health	system	governance	framework	reviews	to	inform	the	basic	structure	of	13	
our	framework,	international	guidance	documents	from	the	WHO,	FAO,	OIE	and	the	EU,	and	sought	14	
the	input	of	over	25	experts	from	international	organizations,	government	ministries,	policy	institutes	15	
and	academic	institutions	to	develop	and	refine	our	framework.	The	framework	consists	of	18	16	
domains	with	52	indicators	that	are	contained	within	three	governance	areas:	"policy	design",	17	
"implementation	tools",	and	"monitoring	and	evaluation".	To	consider	the	dynamic	nature	of	AMR,	18	
the	framework	is	conceptualized	as	a	cyclical	process,	which	is	responsive	to	the	context	and	allows	19	
for	continuous	improvement	and	adaptation	of	AMR	NAPs.	20	
	21	
Key	messages	22	
• Antimicrobial	Resistance	(AMR)	is	one	of	the	most	pressing	and	complex	issues	today,	with	23	
multi	drug-resistant,	extensively	drug-resistant,	and	even	pan	drug-resistant	organisms	24	
emerging.	25	
• AMR	is	driven	by	inter-related	dynamics	in	the	human,	animal,	and	environmental	health	26	
sectors,	which	makes	governance	challenging.		27	
• Strengthening	governance	of	AMR	policies	at	all	levels;	global,	national,	regional	and	local,	is	28	
essential	to	tackling	AMR.	To	date,	no	comprehensive	framework	for	the	governance	of	AMR	29	
National	Action	Plans	(NAPs)	has	been	developed.	30	
• To	our	knowledge,	this	is	the	first	study	that	has	developed	a	governance	framework	for	AMR	31	
NAPs,	based	on	a	systematic	review	of	the	literature,	international	guidance,	and	over	20	32	
experts	from	various	international	organizations,	government	ministries,	policy	institutes	and	33	
academic	institutions	34	
• The	framework	is	conceptualized	as	a	cyclical	process	between	the	three	governance	areas;	35	
policy	design,	implementation	tools,	and	monitoring	and	evaluation.	36	
• Within	policy	design,	improving	strategic	vision,	coordination,	participation,	accountability,	37	
responsibility,	sustainability,	and	equity	were	identified	as	key	to	strengthening	governance.	38	
• Implementation,	surveillance,	antimicrobial	stewardship,	infection	prevention	and	control,	39	
education,	public	awareness,	medicines	regulation,	and	fostering	R&D	and	facilitating	market	40	
access	to	novel	products	were	all	identified	as	essential	tools.	41	
• To	ensure	NAPs	can	adapt	and	continually	improve,	feedback	mechanisms,	reporting	and	42	
research	to	understand	the	drivers	of	AMR,	were	identified	as	crucial	components	to	allow	43	
monitoring	and	evaluation.	44	
• To	build	on	this	governance	framework,	there	is	a	need	for	international	leadership	to	45	
develop	consensus	and	engagement	from	national	policy-makers	to	strengthen	governance	in	46	
AMR	NAPs.	47	
	48	
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	 	50	
Introduction	51	
The	problem	of	antimicrobial	resistance	(AMR)	is	one	of	the	most	pressing	and	complex	current	public	52	
health	 issues.	 Today,	 multi	 drug-resistant,	 extensively	 drug-resistant,	 and	 even	 pan	 drug-resistant	53	
organisms	are	a	challenge	for	healthcare-systems	of	varying	stages	of	development.	If	not	combatted	54	
timely	 and	 effectively,	 AMR	 can	 potentially	 lead	 to	millions	 of	 preventable	 deaths	 per	 year	 and	 to	55	
hundreds	 of	 billions	 of	 economic	 costs	 annually,	 due	 to	 losses	 in	 international	 trade	 or	 livestock	56	
production	and	increased	healthcare	expenditure.
1
	Following	the	adoption	of	the	Global	Action	Plan	on	57	
AMR	by	the	World	Health	Assembly	 in	2015,
2
	many	countries	have	refined	or	developed	their	AMR	58	
national	action	plans	(NAPs)	in	accordance	with	the	internationally	recognized	‘One	Health’	approach	59	
which	requires	policies	to	be	developed	and	implemented	inter-sectorally	across	human,	animal,	and	60	
environmental	health.	Here,	we	present	an	AMR	governance	framework	with	a	dual	purpose:	as	a	tool	61	
for	 policy-makers	 to	 both	 develop	 and	 improve	 AMR	 NAPs,	 and	 to	 also	 facilitate	 an	 objective	62	
assessment	of	AMR	NAPs	to	increase	accountability.		63	
Defining	Governance	64	
Definitions	of	governance	have	 their	origins	 in	 the	multilateral	development	 institutions	of	 the	 late	65	
1980s	and	1990s.	However,	defining	governance	remains	challenging	and	complex.	It	is	helpful	to	start	66	
by	defining	what	governance	is	not,	i.e.	it	is	not	synonymous	with	government.	Addressing	governance	67	
issues	 therefore	 does	 not	 exclusively	 rest	 on	 actions	 of	 governments,	 but	 also	 on	 other	 societal	68	
organizations,	how	they	relate	to	the	public,	and	how	decisions	are	taken.3	Various	efforts	to	define	69	
governance	have	been	undertaken	and	two	widely	referenced	definitions	have	been	outlined	by	the	70	
United	Nations	Development	Programme	(UNDP)	and	the	WHO.	The	UNDP	encompasses	“five	good	71	
governance	principles”:	legitimacy	and	vote,	direction,	performance,	accountability,	and	fairness.4	The	72	
definition	 recognizes	 that	 these	 principles	 sometimes	 overlap	 and	might	 even	 be	 conflicting,	 their	73	
implementation	is	dependent	on	the	context,	the	application	of	these	principles	is	complex,	and	that	74	
good	governance	needs	to	consider	how	power	is	exercised.		75	
Beside	this	more	general	definition,	governance	has	been	defined	more	explicitly	from	a	health-systems	76	
perspective,	starting	with	the	World	Health	Report	2000.5	Here,	governance	is	discussed	as	a	form	of	77	
stewardship,	seen	as	“the	careful	and	responsible	management	of	the	well-being	of	the	population”.	78	
The	role	of	the	government	is	outlined	as	one	of	“oversight	and	trusteeship”,	which	requires	“vision,	79	
intelligence	and	influence”.	In	2002,	the	WHO	defined	governance	further	by	outlining	six	domains	or	80	
sub-functions;	 generation	 of	 intelligence,	 formulating	 strategic	 policy	 direction,	 ensuring	 tools	 for	81	
implementation	 (powers,	 incentives	and	sanctions),	building	coalitions	 /	partnerships,	ensuring	a	 fit	82	
between	policy	objectives	and	organizational	structure	and	culture,	and	ensuring	accountability.6	Later,	83	
within	 the	2007	WHO	Framework	 for	Action,	 these	principles	were	cemented	as	one	of	 the	six	key	84	
building	blocks	of	a	health	system,7	under	the	domain	of	‘leadership	and	governance’.	85	
Governance	in	the	context	of	AMR	National	Action	Plans	86	
Understanding	what	good	governance	translates	to	within	the	context	of	AMR	national	action	plans	is	87	
a	different	matter.	The	complex	nature	of	the	emergence	and	spread	of	AMR	globally	and	the	political-88	
economic	features	of	health	systems	pose	challenges	that	mandate	effective	governance	for	successful	89	
implementation	of	AMR	policies.
8,9
	AMR	is	driven	by	inter-related	dynamics	in	the	human,	animal,	and	90	
environmental	health	sectors,	so	actions	to	address	AMR	should	include	mechanisms	that	coordinate	91	
AMR	policy	inter-sectorally.	Previous	lack	of	international	agreement	regarding	the	direction	of	efforts	92	
to	tackle	AMR	has	allowed	the	discussion	to	be	shaped	by	a	“war	on	superbugs”	or	“post-antibiotic	93	
apocalypse”	discourse,	which	has	put	much	emphasis	on	the	discovery	of	new	antimicrobials	through	94	
pharmaceutical	innovation	and	too	little	priority	on	reduction	of	antimicrobial	use,	and	on	prevention	95	
and	control	of	infections.	Furthermore,	the	complexity	of	AMR	also	necessitates	policies	that	range	in	96	
diversity	 from	 surveillance,	 awareness,	 to	 regulation,	 stewardship,	 and	 infection	 prevention	 and	97	
control,	each	in	the	context	of	human,	animal,	and	environmental	health.		98	
Given	these	challenges,	there	has	been	considerable	interest	in	governance	within	AMR	policy.	In	an	99	
analysis	of	AMR	policies	in	29	European	Union/European	Economic	Area	(EU/EEA)	countries,	the	Third	100	
Report	on	Implementation	of	the	Council	Recommendation	on	prudent	use	of	antimicrobial	agents	in	101	
human	medicine	 suggested	 the	need	 for	 prioritising	 governance	within	 national	 policies	 to	 contain	102	
AMR.
10
	The	Food	and	Agriculture	Organization	of	the	United	Nations	(FAO),	the	World	Organisation	for	103	
Animal	Health	(OIE)	and	the	World	Health	Organization	(WHO)	together	form	a	tripartite	which	has	104	
produced	a	manual	for	developing	NAPs	on	AMR	that	emphasizes	the	establishment	of	a	governance	105	
mechanism	 and	 the	 undertaking	 of	 a	 thorough	 situational	 analysis	 as	 key	 for	 the	 development	 of	106	
NAPs.
11
	The	global	tripartite	database	on	country	progress	has	been	a	first	step	towards	monitoring	107	
AMR	NAPs	on	a	global	scale.
12
	The	goal	of	the	database	is	to	provide	“baseline	information	on	the	status	108	
of	 countries”	 regarding	 the	 implementation	 of	 the	Global	 Action	 Plan	 and	 actions	 to	 address	 AMR	109	
across	all	sectors.	 It	provides	crucial	 initial	 information	such	as	the	existence	of	a	 ‘One	Health’	NAP,	110	
surveillance	of	antibiotic	use	in	human	and	animal	health,	training	of	veterinary	and	health	personnel	111	
and	the	presence	of	public	awareness	campaigns,	although	to	date	its	data	collection	is	broad	and	lacks	112	
detail.		113	
In	2018,	a	discussion	paper	on	AMR	NAPs	from	the	Interagency	Coordination	Group	on	Antimicrobial	114	
Resistance	(IACG)	has	concluded	that	in	most	countries,	the	greatest	challenge	is	not	writing	a	NAP	but	115	
implementing	 it	 and	 demonstrating	 sustained	 action,	 and	 that	 the	 following	 factors	 make	 the	116	
implementation	 of	 NAPs	 particularly	 difficult:	 awareness	 and	 political	 will,	 finance,	 coordination,	117	
monitoring	 and	 data	 and	 technical	 capacity.
13
	 The	 IACG	 framework	 for	 action,14	 highlights	 system	118	
strengthening,	governance,	coordination,	coalition	building	and	political	commitment	as	key	enablers	119	
for	sustainable	action	at	both	global	and	national	 levels.		 In	the	IACG’s	final	report	to	the	secretary-120	
general	of	the	United	Nations	(UN),15	the	need	to	accelerate	the	development	and	implementation	of	121	
One	Health	AMR	NAPs	is	again	highlighted.	The	IACG	rightly	emphasises	that	strengthening	governance	122	
at	all	levels	of	AMR	policy;	global,	national,	regional	and	local,	is	essential	to	tackling	AMR.	Linking	global	123	
and	national	governance,	the	IACG	has	recommended	that	tripartite	agencies	strengthen	One	Health	124	
actions	based	on	country	priorities	and	needs	supported	by	the	urgent	establishment	of	a	“One	Health	125	
Global	Leadership	Group”	on	AMR.15	The	IACG	has	also	recommended	that	the	UN	secretary-general,	126	
in	 close	 collaboration	 with	 the	 tripartite	 agencies,	 UN	 Environment	 and	 other	 international	127	
organizations,	convene	an	independent	panel	on	evidence	for	action	against	AMR	to	support	member	128	
states	to	develop	evidence	based	policies.15	129	
In	 summary,	 the	 inherent	 complexities	 of	 the	 drivers	 of	 AMR	 demand	 a	 systematic	 approach	 to	130	
governance.	However,	 to	date,	no	comprehensive	 framework	for	 the	governance	of	NAPs	has	been	131	
developed	and	there	is	a	need	for	increased	clarity	in	this	area.	To	address	this	unmet	need,	this	paper	132	
presents	the	development	of	an	AMR	governance	framework	for	NAPs	and	the	methods	used	during	133	
its	development.		134	
Methods		135	
We	approached	the	objectives	in	four	stages	(Table	1).	First,	we	searched	Medline,	EMBASE,	and	Global	136	
Health	databases	to	identify	pre-existing	AMR	governance	frameworks.	We	then	performed	a	second	137	
search	 of	 systematic	 and	 non-systematic	 reviews	 of	 health-related	 governance	 frameworks	 again	138	
searching	Medline,	 EMBASE,	 and	Global	Health	 databases	 to	 inform	 the	 initial	 development	 of	 the	139	
framework.	 To	 be	 included,	 the	 publications	 had	 to	 provide	 sufficient	 information	 on	 the	 domains	140	
within	the	frameworks	included	and	had	to	be	related	to	health.	We	choose	to	analyse	systematic	and	141	
non-systematic	 reviews	 as	 health	 system	governance	 is	 a	 previously	well-researched	 area,	 and	 this	142	
strategy	allowed	us	to	comprehensively	review	a	large	body	of	evidence	in	an	efficient	manner.	Both	143	
searches	 were	 performed	 up	 to	 30th	 April	 2018;	 their	 search	 strategies	 can	 be	 found	 in	 the	144	
supplementary	material.	145	
Data	 was	 abstracted	 from	 each	 identified	 framework	 using	 a	 standardized	 extraction	 form.	 The	146	
following	information	was	collected:	1)	first	author	name;	2)	year	and	country	of	publication;	3)	name	147	
of	the	framework;	and	4)	all	domains	that	constitute	the	framework.	The	search	and	data	extraction	148	
process	were	independently	performed	and	agreed	upon	by	the	co-authors.	We	included	domains	in	149	
the	initial	framework	if	they	were	included	in	more	than	a	third	of	the	frameworks	reviewed	(appendix	150	
A).	This	approach	was	taken	to	capture	the	most	commonly	utilised	governance	principles,	and	the	co-151	
author’s	judged	the	cut-off	value	to	be	high	enough	to	provide	sufficient	inclusiveness.	152	
	153	
	154	
155	
Table	1.	Stages	of	Developing	and	Refining	the	AMR	Governance	Framework.	156	
*WHO,	World	Health	Organization;	 **OECD,	Organisation	 for	 Economic	 Co-operation	 and	Development;	 ***LSE,	 London	157	
School	of	Economics	and	Political	Science.		158	
	159	
	160	
	 	161	
STAGE AIMS	 METHODS	USED 
I.	Search	for	
existing	AMR	
governance	
frameworks	
To	identify	previously	
published	AMR	
governance	
frameworks	
Search	of	Google	Scholar,	Medline,	Embase,	Global	Health	
using	the	search	terms	“antimicrobial”,	“antimicrobic”,	
“antibiotic”,	“antibacterial”,	and	“governance”.	
	
Academic	publications,	reports,	and	grey	literature	
considered	
II.	Systematic	
review	of	
health	system	
governance	
framework	
reviews	
To	identify	previously	
published	health	
system	governance	
frameworks	
	
Search	of	the	literature	using	Medline,	Embase,	Global	
Health	using	the	search	terms	“governance”,	and	
“framework”.	
	
Academic	publications,	reports,	and	grey	literature	
considered	
III.	Review	of	
international	
guidance	
documents	
To	identify	all	
relevant	policy	
options	and	
strategies	
	
To	ensure	
comprehensiveness	
of	implementation	
tools	
Review	of	key	international	guidance	documents:		
• WHO:	Global	Action	Plan	on	Antimicrobial	Resistance	
(2015)2	
• The	OIE	Strategy	on	Antimicrobial	Resistance	and	the	
Prudent	Use	of	Antimicrobials	(2016)16	
• The	FAO	Action	Plan	on	Antimicrobial	Resistance	2016-
2020	(2016)17	
• FAO/OIE/WHO:	 A	 Manual	 for	 developing	 National	
Action	Plans	(2016)11	
• EU:	 A	 European	 One	 Health	 Action	 Plan	 against	
Antimicrobial	Resistance	(2017)18	
IV.	Expert	
review	of	draft	
framework	
and	synthesis		
To	expand	and	revise	
the	domains	and	
indicators	in	all	
governance	areas	
	
To	validate	the	
framework	and	
potential	value	for	a	
range	of	stakeholders	
	
To	refine	and	
propose	final	
framework	
	Experts	consulted	from:	
	
5	International	Organizations	
8	Government	Departments	
8	Universities	
2	Policy	Institutes	
10	Countries	
5	Continents	
	
(See	Supplementary	Material)	
	
		
Expert	consultations	through:	
	
Written	review	feedback	
	
Teleconferences	
	
To	account	for	the	distinctive	aspects	of	governance	in	the	context	of	national	AMR	policy,	we	expanded	162	
and	 refined	 the	 AMR	 governance	 framework	 in	 the	 third	 stage	 by	 reviewing	 the	 five	most	 recent	163	
guidance	documents	from	four	key	international	organizations	–	the	WHO,	the	OIE,	the	FAO	as	well	as	164	
the	EU.	These	four	organisations	are	major	actors	in	international	AMR	policy	development	and	have	a	165	
precedent	of	producing	guidance	regarding	national	AMR	policies	for	their	member	states.	166	
To	 increase	 the	 validity	 of	 the	 framework	 and	 to	develop	pre-existing	 and	 additional	 indicators	we	167	
sought	review	of	the	framework	and	its	components	by	experts	from	multiple	sectors,	disciplines,	and	168	
geographies	 in	 the	 fourth	 stage.	 A	 judgement	 sample	 was	 used	 for	 this	 purpose.
19
	 Experts	 were	169	
approached	based	on	a	combination	of	factors	such	as	the	length	of	their	experience	in	the	field	of	170	
AMR,	their	wide	perspective	on	the	development	of	AMR	NAPs	(both	policy-makers	and	academics),	171	
and	their	interest	in	governance	challenges	associated	with	AMR	policy.	In	total,	a	range	of	experts	from	172	
five	 international	 or	 intergovernmental	 organisations	 (WHO,	 PAHO,	 OECD,	 European	 Commission,	173	
European	Centre	for	Disease	Prevention	and	Control),	eight	universities,	eight	government	ministries,	174	
and	 two	 policy	 institutes	 (Chatham	 House	 and	 PEW	 Charitable	 Trust)	 provided	 feedback	 (see	175	
acknowledgements).	The	final	step	of	stage	IV	involved	synthesizing	the	feedback	and	findings	from	the	176	
preceding	steps	to	produce	a	refined	and	final	framework.		177	
Results		178	
Stages	 I	 and	 II:	 Systematic	 review	 of	 AMR	 governance	 frameworks	 and	 health	 system	 governance	179	
framework	reviews	180	
The	main	 results	 of	 all	 stages	 are	 summarized	 in	 Table	 2.	 The	 systematic	 search	 for	 previous	AMR	181	
governance	frameworks	yielded	no	results	(see	supplementary	material).	The	process	of	identification	182	
and	study	selection	for	the	systematic	review	of	health	system	governance	reviews	is	summarized	in	183	
Figure	1.		184	
			 	 				Figure	1.	Flow	chart	of	study	selection	(stage	II)	185	
From	a	total	of	827	records	that	were	title-	and	abstract-screened,	822	were	excluded	as	they	were	not	186	
reviews	of	health	system	governance	frameworks.	The	full	text	of	the	remaining	four	publications	were	187	
reviewed,	 leading	 to	 the	 inclusion	 of	 three	 non-systematic	 reviews	 and	 one	 systematic	 review	 for	188	
qualitative	 assessment.20–23	 Twenty-six	 governance	 frameworks	 were	 identified	 in	 those	 four	189	
publications	 and	 the	 11	 most	 frequent	 key	 governance	 domains	 across	 these	 frameworks	 were	190	
identified.	The	criteria	for	the	inclusion	of	commonly	used	governance	domains	were	present	in	more	191	
than	 a	 third	 of	 governance	 frameworks,	 a	 cut-off	 agreed	 upon	 by	 consensus	 of	 co-authors	192	
(supplementary	material).	The	final	component	of	stage	II	was	the	formation	of	the	basic	structure	of	193	
the	framework	by	grouping	these	eleven	domains	in	three	broader	governance	areas:	‘Policy	Design’,	194	
‘Implementation	tools’,	and	‘Monitoring	and	Evaluation’.		195	
Table	2.	Summary	of	development	of	the	AMR	Governance	Framework	196	
STAGE MAIN	RESULTS 
I.	Search	for	existing	AMR	
governance	frameworks	
No	AMR	governance	frameworks	identified	
II.	Systematic	review	of	
health	system	governance	
reviews	
Review	of	26	health	system	governance	frameworks	à	Basic	structure	of	
AMR	governance	framework	(3	governance	areas,	11	governance	
domains):	
Area	 Domains	
Policy	design	 Strategic	Vision,	Participation,	Coordination,	
Accountability,	Transparency,	Sustainability,	
Equity	
Implementation	tools	 Generation	of	Information	and	Intelligence,	
Regulation	
Monitoring	and	evaluation	 	Effectiveness,	Responsiveness		
	
III.	Review	of	international	
guidance	documents	
Domains	
• 7	domains	added:	Surveillance,	Stewardship,	Infection	Prevention	and	
Control,	Education,	Public	Awareness,	Fostering	R&D	of	Novel	
Antimicrobials/Alternatives,	AMR	Research	
• One	domain	removed:	Generation	of	Information	and	Intelligence.		
Replaced	by	the	following	domains:	Surveillance,	AMR	research,	and	
Fostering	of	R&D	of	Antimicrobials/Alternatives	
Indicators	
• 34	indicators	developed	(see	supplementary	material)	
IV.	Expert	review	of	draft	
framework	and	synthesis		
Domains	
• 4	domains	renamed:	Antimicrobial	Stewardship,	Medicines	
Regulation,	Feedback	Mechanisms,	Fostering	R&D	and	Facilitating	
Market	Access	to	Novel	Products	
• One	domain	added:	Reporting	
Indicators	
• 34	indicators	reformulated/reworded	and	explanatory	text	added	
• 18	indicators	added	
Agreement	on	basic	structure	of	the	framework	
Stage	III:	Review	of	international	guidance	documents		197	
Reviewing	 the	 five	 international	 guidance	 documents	 resulted	 in	 the	 addition	 of	 seven	 domains:	198	
‘Surveillance’,	 ‘Stewardship’,	 ‘Infection	 Prevention	 and	 Control’,	 ‘Education’,	 ‘Public	 Awareness’,	199	
‘Fostering	the	research	and	development	(R&D)	of	Novel	Antimicrobials/Alternatives’,	‘AMR	Research’,	200	
some	of	which	replaced	the	previous	domain;	‘Generation	of	Information	and	Intelligence’	as	well	as	201	
the	extraction	of	34	initial	indicators	(see	supplementary	material).	These	domains	and	indicators	were	202	
selected	as	the	first	step	towards	developing	a	governance	framework	for	the	specific	context	of	AMR	203	
NAPs.	204	
The	wording	of	the	indicators	was	selected	in	such	a	way	that	they	could	offer	binary	answers	and	be	205	
applied	using	a	combination	of	publicly	available	resources	and	interviews	of	country	experts	to	allow	206	
a	feasible	and	practical	application	of	the	framework	to	a	country’s	AMR	NAP.	The	justification	for	each	207	
of	these	indicators	is	explored	further	within	the	framework.		208	
Stage	IV:	Expert	review	of	draft	framework	and	synthesis	209	
Throughout	several	iterations	of	the	governance	framework,	we	received	expert	feedback	via	email	and	210	
teleconferences.	In	three	cases	we	received	consolidated	feedback	based	on	the	responses	of	multiple	211	
individuals	 in	 those	 organizations	 (see	 acknowledgements).	 The	 experts	 agreed	 on	 the	 general	212	
structure	 of	 three	 governance	 areas	 and	 most	 domains.	 Instead,	 experts	 primarily	 focused	 their	213	
feedback	on	the	improvement	and	development	of	the	indicators.	This	resulted	in	the	reformulation	214	
and	rewording	of	initial	34	indicators,	the	addition	of	18	further	indicators	as	well	as	the	addition	of	one	215	
further	domain	(‘Reporting’)	to	feed	into	the	final	‘AMR	Governance	Framework’.	216	
Governance	Framework	217	
Eighteen	 separate	 domains	were	 incorporated	 into	 the	 framework	within	 three	 governance	 areas:	218	
‘Policy	 Design’,	 ‘Implementation	 Mechanisms’,	 and	 ‘Monitoring	 and	 Evaluation’	 (Figure	 2).	 At	 the	219	
structural	level,	the	framework	represents	an	ongoing	cycle	of	review	and	evaluation	processes.	The	220	
aim	of	this	cyclical	design	is	to	conceptualize	AMR	governance	not	as	a	static	but	dynamic	and	ongoing	221	
process	 that	 constantly	 improves	 and	 adjusts,	 according	 to	 lessons	 learned	 from	 monitoring	 and	222	
evaluation.	223	
	224	
Figure	2	AMR	governance	framework:	three	areas	and	18	domains.	225	
The	first	governance	area	–	‘Policy	design’	–	is	concerned	with	general	and	procedural	issues	of	AMR	226	
NAPs,	such	as	wide	participation	in	the	development	of	NAPs,	coordination	across	the	multiple	sectors,	227	
and	 levels	 of	 service	 delivery	 (at	 national	 and	 sub-national	 levels),	 transparency,	 sustainability	 and	228	
equity	 implications	 of	 AMR	 policies	 as	 well	 as	 determining	 who	 is	 ultimately	 accountable	 to	 the	229	
government	for	achieving	the	objectives	of	the	NAP	(Table	3).		230	
The	 second	 governance	 area	 -	 ‘Implementation	 tools’	 –	 consists	 of	 crucial	 interventions	 contained	231	
within	 WHO/FAO/OIE/EU	 guidance.	 Here,	 three	 of	 the	 domains	 determine	 whether	 surveillance,	232	
antimicrobial	 stewardship	 programmes,	 and	 infection	 prevention	 and	 control	 measures	 are	233	
implemented	across	 the	 ‘One	Health’	 spectrum.	Other	domains	 in	 this	governance	area	encompass	234	
further	fundamental	AMR	tools	such	as	education	of	relevant	professionals,	public	awareness	activities,	235	
and	medicines	regulation.	‘Implementation	tools’	also	examine	whether	there	are	appropriate	policies	236	
and	incentives	in	place	to	encourage	research	and	development	of	novel	antimicrobials	and	alternatives	237	
(Table	4).	238	
Domains	 within	 the	 third	 governance	 area	 –	 ‘Monitoring	 and	 Evaluation’	 –	 include	 reporting	 and	239	
feedback	 mechanisms	 that	 allow	 for	 regular	 review	 and	 evaluation	 of	 AMR	 NAPs,	 as	 well	 as	 the	240	
effectiveness	 and	 cost-effectiveness	 dimensions	 of	 different	 aspects	 of	 the	 NAPs.	 Finally,	 the	 non-241	
therapeutic	AMR	research	domain	considers	whether	there	is	a	national	multidisciplinary	‘One	Health’	242	
research	agenda	which	aims	to	understand	the	drivers	of	and	potential	strategies	to	combat	AMR	(Table	243	
5).		244	
For	each	of	the	18	domains,	multiple	indicators	were	developed	to	signal	whether	the	requirements	for	245	
the	domains	are	fulfilled.	In	total,	52	indicators	were	derived	and	are	outlined	in	detail,	 including	an	246	
explanation	of	their	rationale	in	Tables	3–5.	 	247	
Table	3.	AMR	Governance	Framework,	Area	1	-	Policy	Design	
	
	Area	1	-	Policy	Design	
Domains	&	Indicators	 Key	Issues		
1	-	Strategic	Vision	
In	the	context	of	AMR,	strategic	vision	is	the	overarching	platform	and	the	statement	
of	goals	and	ideas	central	to	the	NAP.24	It	is	important	to	consider	whether	a	NAP	has	
drawn	on	an	up-to-date	country	specific	situational	analysis	regarding	the	extent	of	
AMR	and	its	drivers.	A	situational	analysis	may	also	inform	the	objectives	outlined	in	
each	national	plan,	where	each	objective	should	be	specific,	measurable,	and	time-
bound.	 Additionally,	 quantitative	 targets	 for	 improving	 antibiotic	 prescription,	
consumption,	 and	 resistance	 in	 both	 human	 and	 animal	 health	 can	 be	 a	 useful	
mechanism	to	focus	actors	towards	a	clear	objective,	although	this	may	only	be	the	
case	 in	 more	 advanced	 NAPs.	 For	 lesser	 developed	 plans,	 there	 should	 be	 an	
incremental	 plan	 in	 place	 to	 improve	 surveillance	 capability	 to	 facilitate	 the	
measurement	and	implementation	of	quantitative	targets.	
	
	
Indicator	
1	
Has	a	situational	analysis	been	conducted	to	determine	the	prevalence	
and	incidence	of	AMR	organisms	in	the	country?		
2	
organismIs	a	national	action	plan	(NAP)	in	place,	if	not	what	is	the	
timeframe	for	developing	and	implementing	the	NAP?	
3	
Are	the	objectives	contained	within	the	NAP	specific,	measurable	and	
time-bound?	
4	
Are	there	quantitative	targets	for	AMR/antimicrobial	use	outlined	in	the	
NAP?	
2	-	Coordination	
The	WHO,	the	FAO,	and	the	OIE	have	outlined	the	need	for	coordination	between	all	
relevant	ministries,	high-quality	laboratories,	medical	and	veterinary	professions	and	
statutory	 bodies,	 research	 and	 academic	 institutes,	 civil	 society	 including	 patient	
organizations	 and	 farmer/agricultural	 organizations,	 food	 and	 pharmaceutical	
industries,	and	wholesale	and	retail	distributors,	through	a	multi-sectoral	‘One	Health’	
policy	approach.11,25,26	Additionally,	recent	reviews	have	highlighted	the	necessity	to	
coordinate	different	 levels	of	human	and	veterinary	health	care	 including	national,	
regional	and	local,	as	well	as	the	horizontal	dimensions.	For	example	in	human	health,	
across	 primary,	 secondary,	 and	 long-term	 care	 and	 in	 animal	 health	 across	 both	
companion	animals	and	livestock	sectors.26,27	Lastly,	it	is	an	important	consideration	
to	 clarify	 if	 there	 is	 an	 intersectoral	 committee	 or	 ministry	 responsible	 for	
implementing	 and	 coordinating	 the	 NAP.	 It	 may	 be	 the	 case	 that	 intersectoral	 is	
chaired	by	a	ministry	with	overarching	responsibility	for	coordination.		
5	
Is	coordination	between	sectors	and	across	different	levels	of	each	
sector	considered?	
6	
Is	there	a	ministry	and/or	intersectoral	committee	responsible	for	
coordination	and	implementation?	
3	-	Participation		
Participation	both	during	conception	and	subsequent	implementation	is	a	particularly	
important	aspect	of	governance	in	the	context	of	AMR	policies,28	as	we	move	towards	
7	
Was	a	high	level	of	stakeholder	participation	facilitated	throughout	the	
development	of	the	NAP?	
a	 ‘One	 Health’	 approach.	 This	 also	 improves	 the	 legitimacy	 of	 AMR	 NAPs	 and	
stakeholder	 engagement	 during	 the	 implementation	 and	 subsequent	 evaluation	
phases.	WHO	guidance	states	that	all	relevant	ministries,	 laboratories,	medical	and	
veterinary	professions	and	statutory	bodies,	 research	and	academic	 institutes,	civil	
society	 including	patient	organizations,	 farmer/agricultural	organizations,	 food	and	
pharmaceutical	 industries,	 regulatory	 authorities	 and	 wholesale	 and	 retail	
distributors	 should	 be	 involved.11	 As	 well	 as	 broad	 stakeholder	 participation,	 to	
promote	evidence-based	policy,	the	inclusion	of	a	technical	advisory	group	or	subject	
matter	 experts	 from	 across	 the	 human,	 animal	 and	 environmental	 health	 sectors	
during	development	offers	further	credibility.		
8	
Are	the	activities	in	the	NAP	inclusive	across	all	'One	Health'-related	
sectors?	If	so,	how,	and	if	not,	why	not?	
9	
Was	there	support	from	a	technical	advisory	group	or	subject	matter	
experts	during	development	of	the	NAP?	
4	-	Accountability	
Accountability	 is	 a	 crucial	 aspect	of	 governance	 in	 any	 context.	Being	accountable	
means	‘having	the	obligation	to	answer	questions	regarding	decisions	and/or	actions’	
and	 can	 be	 understood	 to	 have	 two	parts;	 explanation	 and	 sanction.29	 	 For	 these	
processes	to	work	effectively,	accountability	mechanisms	should	be	as	uncomplicated	
as	possible	and	include	mutually	agreed	measurable	outcomes	so	they	can	facilitate	
constructive	two-way	dialogue.	In	terms	of	an	AMR	NAP,	it	is	crucial	that	whichever	
entity	is	responsible	for	coordination	and	implementation	is	accountable	to	a	higher	
body	 in	 government.	 Furthermore,	 to	 improve	 accountability,	 there	 should	 be	 a	
person	nominated	within	each	sector	responsible	for	implementation.	
10	
Is	there	an		ministry	and/or	intersectoral	committee	responsible	for	
coordination	and	implementation	which	is	accountable	to	the	
Government?	
11	
Is	a	responsible	person	nominated	in	each	sector	and	do	agreements	
exist	regarding	what	happens	if	objectives	are	not	met?	
5	-	Transparency	
Transparency	 can	 be	 understood	 as	 ensuring	 AMR	 policy	 development,	
implementation,	and	evaluation	occur	in	an	open	and	accessible	manner.	In	terms	of	
AMR	NAPs,	 it	 is	 important	the	plan	itself,	progress	reports,	and	funding	allocations	
are	published	with	open	access	to	the	public,	subject	to	agreement	of	contributors	to	
the	plan.	Further	transparency	can	be	achieved	by	providing	open	access	to	AMR	and	
antimicrobial	 use	 data,	 with	 adequate	 consideration	 of	 data	 governance.	 This	
information	must	also	be	presented	 in	an	understandable	 format	 to	ensure	public	
engagement,	 which	 can	 encourage	 greater	 political	 awareness	 and	 civil	 society	
involvement	in	AMR	policy.30	
	
12	 Is	the	complete	NAP	publicly	available?	
13	 Are	all	progress	reports	publicly	available?	
14	 Is	all	funding	information	publicly	available?	
15	 Is	all	AMR/antimicrobial	use	surveillance	data	publicly	available	?	
6	-	Sustainability		
Sustainability	 should	 be	 a	 key	 objective	 of	 any	 AMR	 NAP,	 as	 any	 positive	 change	
should	aim	to	be	consistent	and	maintained.	Without	a	dedicated	budget	for	both	the	
NAP	and	any	intersectoral	committee,	it	is	likely	that	actors	will	have	limited	resources	
to	implement	AMR	polices.	Furthermore,	strategic	consideration	of	budget	allocation	
	AMR,	antimicrobial	resistance;	FAO,	The	Food	and	Agriculture	Organization	of	the	United	Nations;	NAP,	national	action	plan;	OIE,	World	Organisation	for	Animal	Health;	
WHO,	World	Health	Organization	
	
	
	
16	
Is	there	either	a	written	mandate	or	voluntary	agreement	from	all	
relevant	sectors	in	place	to	implement	the	NAP?	
and	assessment	for	potential	gaps	in	funding	is	desirable.	The	sustainability	of	an	AMR	
NAP	may	also	rely	upon	its	legitimacy,	which	is	crucial	for	the	ongoing	engagement	of	
all	 stakeholders.	 This	 can	 be	 achieved	 through	 either	 the	 provision	 of	 a	 clear	
government	 mandate	 or	 a	 voluntary	 agreement	 from	 all	 relevant	 sectors	 to	
implement	the	NAP.	The	ongoing	support	of	an	interdisciplinary	technical	group	can	
offer	further	sustainability,	ensuring	the	NAP	remains	evidence-based	and	utilizes	all	
recent	findings	from	monitoring	and	evaluation	processes.	Finally,	to	achieve	ongoing	
support	and	promote	advocacy,	the	objectives	within	AMR	NAPs	can	be	aligned	with	
pre-existing	 initiatives	 such	 as	 National	 Health	 Policies,	 Strategies	 and	 Plans	
(NHPSPs),31	 National	 Action	 Planning	 for	 Health	 Security	 (NAPHS),32	 and	 the	 UN	
Sustainable	Development	Goals	(SDGs).33	
17	
Are	there	dedicated	budgets	in	place	to	implement	specific	activities	in	
the	NAP?	
18	
Is	there	an	assessment	of	future	budget	requirements	for	different	
activities	listed	in	the	NAP?	
19	
Is	there	ongoing	support	from	a	technical	advisory	group	or	subject	
matter	experts	during	implementation,	monitoring	and	evaluation	of	
the	NAP?	
7	-	Equity	
In	 all	 countries,	 it	 may	 be	 the	 case	 that	 certain	 communities	 do	 not	 receive	
appropriate	and	equitable	access	to	antimicrobials.34,35	The	concepts	of	responsible	
use	 and	 equitable	 access	 are	 inextricably	 linked,	 and	 the	 focus	 should	 be	 on	
facilitating	 equitable	 access	 to	 the	 right	 antimicrobial,	 at	 the	 right	 time,	 based	on	
clinical	need.		Shortages	of	antimicrobials	can	drive	AMR,	as	prescribers	have	to	resort	
to	 less-effective	 treatments,36	 or	 to	 a	 broader	 spectrum	 of	 antimicrobial	 than	 is	
necessary.	 	 Moreover,	 high	 out-of-pocket	 payments	 can	 create	 an	 incentive	 for	
providers	to	inappropriately	prescribe	antibiotics	and/or	result	in	inequitable	access	
to	 antimicrobials.37	 	 Therefore,	 as	 a	 key	 component	 to	 tackle	 AMR,	 NAPs	 should	
consider	 how	 best	 to	 balance	 responsible	 use	 and	 equitable	 access	 to	 essential	
antimicrobials.38		
20	
Does	the	NAP	include	both	encouraging		responsible	use	and	facilitating	
equitable	access	to	existing	essential	antimicrobials?	
Table	4.	AMR	Governance	Framework,	Area	2	-	Implementation	Tools	
	
Area	2	-	Implementation	Tools	
Domains	&	Indicators	 Key	Issues	
8	-	Surveillance	
Surveillance	is	fundamental	for	the	planning,	conduct,	and	evaluation	of	all	other	
AMR	policies.26	It	can	facilitate	accountability	mechanisms	and	the	use	of	consistent	
metrics	are	an	important	tool	for	cross-country	comparisons	of	progress	in	reducing	
AMR,39	through	initiatives	such	as	the	Global	Antimicrobial	Resistance	Surveillance	
System	(GLASS)	and	the	work	of	agencies	such	as	the	European	Centre	for	Disease	
Prevention	and	Control	 (ECDC).	 It	 is	 important	 that	national	surveillance	systems	
involve	 data	 collection	 and	 assessment	 of	 both	 antimicrobial	 consumption	 and	
resistance	across	human,	animal,	and	environmental	health	sectors,	as	well	as	the	
provision	of	adequate	laboratories,	equipment	and	technical	expertise	necessary.40–
43	Surveillance	metrics	should	include	the	overall	quantity	of	antimicrobials	used	as	
well	as	an	assessment	of	both	appropriate	and	inappropriate	use.	It	is	also	important	
that	 there	 is	 adequate	 laboratory	 capacity	and	capability	 supported	by	a	 regular	
programme	of	external	quality	assessments.43		
	
Indicator	
21	 Is	there	a	national	surveillance	system	for	resistant	organisms	across	the	
human,	animal,	and	the	environmental	health	sectors?organism	
22	
Is	there	a	national	surveillance	system	for	levels	of	antimicrobial	use	in	
animals	and	humans?	
23	
Is	there	adequate	laboratory	capacity	and	capability	supported	by	regular		
external	quality	assessments?	
9	-	Antimicrobial	Stewardship	
Antimicrobial	stewardship	is	defined	as	a	coherent	set	of	actions	designed	to	use	
antimicrobials	 responsibly	 and	 refers	 to	 all	 actors	 and	 stakeholders	 seeing	 their	
responsibilities,	ownership	and	interest	in	the	issue.44	In	human	health,	stewardship	
programmes	can	help	clinicians	improve	patient	safety,	reduce	treatment	failure,	
and	increase	the	use	of	prophylactic	measures.45	Stewardship	programmes	should	
be	complemented	by	national	guidelines	on	antimicrobial	use	and	 the	 indication	
and	interpretation	of	rapid	diagnostic	tests.45	In	animal	health,	national	guidelines	
can	 be	 utilized	 to	 encourage	 appropriate	 antibiotic	 use	 and	 to	 improve	 both	
terrestrial	and	aquatic	animal	health.46,47	Comprehensive	national	guidelines	should	
cover	 a	 wide	 range	 of	 indications,	 and	 not	 only	 a	 few	 common	 infections.	
Stewardship	 programmes	 should	 also	 include	 monitoring	 adherence	 to	 these	
guidelines,	which	may	require	individual	physician	and	patient	level	data,38	or	in	the	
case	of	 animal	 health,	 the	monitoring	of	 farm-level	 antimicrobial	 usage	 and	and	
appropriate	drug	selection	and	use.47	Financial	incentives	and	penalties	have	also	
been	utilised	to	encourage	healthcare	professionals	to	reduce	antimicrobial	use	and	
24	
Are	there	stewardship	programmes	across	human	and	animal	health	
sectors?	
25	
Are	rapid	diagnostic	tools	widely	available	and	in	regularly	use?	
if	so,	do	national	guidelines	regarding	their	indication	and	interpretation	
exist?		
26	
Are	there	up-to-date	national	guidelines	on	antimicrobial	use	and	rapid	
diagnostic	tools	across	a	wide	range	of	settings	in	animal	and	human	
health?		
27	
	
Is	there	any	use	of	financial	and	non-financial	incentives/penalties	in	
animal	and	human	health	to	reduce	inappropriate	use	of	antibiotics?		
	
adhere	 to	national	 guidelines.48	However,	non-financial	 incentives	 such	as	public	
reporting	and	peer	comparison	can	also	be	utilised.49	Lastly,	as	discussed	in	Domain	
7	 stewardship	programmes	should	both	 limit	 inappropriate	use	of	antimicrobials	
but	also	facilitate	equitable	and	timely	access	to	appropriate	antimicrobials	when	
needed.50	
10	-	Infection	Prevention	and	Control	
Infection	prevention	and	control	(IPC)	serves	as	an	important	policy	objective	in	all	
settings	 that	 aims	 to	 reduce	 the	 transmission	 of	 multi-drug	 resistant	 bacteria,	
minimize	 the	 overall	 risk	 of	 infection,	 and	 decrease	 the	 overall	 need	 for	
antimicrobials.	Within	AMR	NAPs,	it	is	important	that	the	plan	includes	IPC	measures	
across	 all	 sectors	 including	 human,	 animal	 and	 environmental	 health.	 In	 human	
health,	 antimicrobial	 stewardship	programmes	have	 shown	 to	be	more	effective	
when	 implemented	 in	 conjunction	 with	 IPC	 measures,	 especially	 hand-hygiene,	
than	when	implemented	alone.51	To	support	implementation,		core	components	of	
infection	control	programmes	in	both	hospital	and	community	settings	should	be	
standardised.52,53	 Multimodal	 IPC	 improvement	 strategies,	 including	 system	
change,	 training	 and	 education,	 monitoring	 and	 feedback	 and	 reminders	 and	
communications	have	been	shown	to	be	effective,	feasible	and	sustainable	across	a	
range	of	settings	in	different	countries.54	Whereas	in	animal	health,	good	husbandry	
practices	 and	 effective	 biosecurity	 measures	 are	 important.55	 Lastly	 waste	
management	 programmes	 should	 aim	 to	 minimise	 environmental	 exposure	 to	
resistant	 organisms.56,57	 As	 part	 of	 a	 NAP,	 national	 guidelines	 for	 IPC	 should	 be	
developed	 to	 standardize	 implementation	 and	 evaluation	 within	 each	 context.	
Similarly,	to	antimicrobial	stewardship,	both	financial	and	non-financial	incentives	
such	as	public	 reporting	and	accreditation	can	be	used	to	 increase	adherence	to	
guidelines	 and	 reduce	 the	 incidence	 of	 infections.58,59	 Lastly,	 immunisation	
programmes	can	be	an	effective	strategy	to	reduce	burden	of	vaccine-preventable	
infections	in	both	human	and	animal	sectors.60	
28	
Are	there	IPC	policies	across	all	levels	of	human,	animal	and	
environmental	health	sectors?	
29	
Are	there	up-to-date	national	guidelines	for	IPC	across	human,	animal	
and	environmental	health	sectors?	
30	
Are	immunisation	programmes	utilised	as	an	approach	to	prevent	
infections	across	human	and	animal	health	sectors?	
31	
Are	financial	and	non-financial	incentives/penalties	for	IPC	policies	
utilised	across	human,	animal	and	environmental	health?	
11	-	Education	
Examples	from	both	the	human	and	the	animal	health	sector	have	shown	how	a	
lack	of	education	can	lead	to	a	lack	of	capacity	to	adopt	standards,	facilitate	control	
policies,	or	implement	guidelines	sufficiently.26	It	is	therefore	essential	for	all	groups	
of	 professionals	 who	 are	 in	 the	 position	 to	 prescribe	 antibiotics	 or	 influence	
antibiotic	 use	 to	 receive	 dedicated	 education	 at	 both	 undergraduate	 and	
postgraduate	 level	about	antimicrobial	stewardship	and	 infection	prevention	and	
control.	 In	 the	 human	 health	 sector,	 medical	 students,	 physicians,	 pharmacists,	
32	
Is	there	certifications	or	programmes	in	place	to	ensure	a	basic	education	
for	all	involved	groups	of	professionals	to	deliver	necessary	
understanding	for	strategies	to	tackle	AMR?	
33	
Is	there	continuing	education	programmes	for	all	involved	groups	of	
professionals	to	ensure	expertise	necessary	for	expanding	knowledge	and	
sustained	efforts	to	tackle	AMR?	
nurses,	midwifes,	dentists,	and	technicians	need	to	be	trained	to	build	the	capacity	
that	 is	 needed	 to	 implement	 guidelines	 and	 objectives.61,62	 At	 national	 and	
institutional	level,	educations	programmes	should	aim	to	foster	a	culture	of	safety	
among	 healthcare	 workers,	 administration	 and	 decision	 makers,	 as	 part	 of	
multimodal	strategies	to	improve	IPC	and	stewardship.63,64	 It	 is	equally	 important	
for	 professionals	 from	 the	 animal	 and	 environmental	 health	 sector	 to	 receive	
training,	 as	well	 as	 professionals	working	 in	 the	 food	 industry	 or	 environmental	
agencies.65	Moreover,	workforce	shortfalls	are	a	persistent	barrier	to	implementing	
policies	 to	 tackle	AMR	 in	many	countries,	particularly	with	 IPC	and	antimicrobial	
stewardship	programmes	 in	human	health.66	However,	many	other	professionals	
such	as	veterinarians,	environmental	health	officers	and	biochemists	are	required	
to	 implement	 AMR	 policies	 in	 animal	 and	 environmental	 health.	 As	 such,	 an	
essential	 component	 of	 any	 AMR	 NAP	 is	 a	 comprehensive	 workforce	 strategy	
responsive	to	local	needs	informed	by	detailed	workforce	planning.		
34	
Is	there	a	workforce	strategy	which	aims	to	deliver	the	sustainable	supply	
of	the	necessary	workforce	required	to	deliver	antimicrobial	stewardship	
and	IPC	policies?	
12	-	Public	Awareness	
Public	awareness	campaigns	can	be	used	in	a	variety	of	settings	to	raise	awareness	
and	promote	best	practices	for	prevention	of	AMR.	Several	countries	have	found	a	
reduction	 in	 the	number	 of	 antibiotic	 prescriptions	 following	 campaigns	 to	 raise	
awareness	about	prudent	use	of	antibiotics	and	AMR.26,67,68	Campaigns	should	be	
implemented	at	national,	regional,	and	local	levels	to	ensure	widespread	coverage,	
and	should	be	ongoing,	rather	than	one-off	efforts.	Educational	campaigns	within	
school-based	curriculum	should	be	considered	to	raise	awareness	about	AMR	from	
a	 young	 age.57	 Furthermore,	 communicating	 the	 concept	 of	 ‘One	 Health’	 can	
improve	 the	public	understanding	of	 the	drivers	of	AMR.	 To	achieve	 sustainable	
behavioural	and	cultural	 change,	 the	most	effective	public	awareness	campaigns	
have	 	 been	 shown	 to	 be	multi-modal,	 utilising	 a	 combination	 of	 print	 and	mass	
media,	 guidelines,	 and	 feedback	 back	 to	 individual	 prescribers.69	 Ideally	 all	
awareness	and	education	 campaigns	 should	be	based	on	 findings	 in	behavioural	
science,	pedagogy,	and	other	behavioural	disciplines	to	increase	effectiveness.		
35	
Are	there	multi-modal	public	awareness	campaigns	that	focus	on	AMR	
and	educational	programmes	(including	school	children)	related	to	AMR?	
36	
Do	the	implemented	public	awareness	campaigns	have	an	ongoing	
character?		
37	
Does	the	conception	of	the	public	awareness	campaign	consider	aspects	
of	behavioural	sciences,	social	science	and	psychology?	
13	-	Medicines	Regulation	
To	 conserve	 the	 use	 of	 currently	 available	 antimicrobials,	 regulation	 has	 been	
utilized	in	a	variety	of	ways.	We	interpret	regulation	as	any	laws,	accreditation	or	
38	
Are	there	regulations	in	place	to	ensure	appropriate	use	of	antimicrobials	
in	human	health?	
financial	incentive/penalties	in	place	with	the	aim	of	reducing	antimicrobial	use.	For	
example,	 many	 countries	 have	 enforced	 legislation	 that	 make	 antimicrobials	
“prescription-only	 status”,	 that	 is	 requiring	 a	 mandatory	 prescription.	 Another	
significant	example,	is	the	Feed	Additives	Regulation	in	the	EU,	which	banned	the	
use	of	antibiotics	as	growth	promoters	in	animal	feed	from	January	2006.70	There	
are	 also	 antimicrobials	 deemed	 critically	 important	 for	 human	 health,	 and	
regulation	 should	 play	 a	 key	 role	 in	 ensuring	 they	 are	 not	 used	 in	 animals.71		
Moreover,	 in	 some	 countries,	 large	 quantities	 of	 substandard,	 expired	 or	
counterfeit	 antimicrobials	 are	 sold,72	 either	 in-person	 or	 online,	 and	 effective	
regulation	is	essential	to	reduce	this	practice.	Regulation	is	also	required	to	ensure	
disposal	of	antimicrobials	takes	place	in	a	manner	which	minimizes	environmental	
exposure.73	 Finally,	 regulation	 is	 utilized	 in	 many	 countries	 to	 ban	 direct	 to	
consumer	 advertising	 (DTCA)	 of	 medications,	 including	 antimicrobials.	 This	 is	
important	 as	 inappropriate	 DTCA	 can	 alter	 public	 expectations	 or	 prescribing	
behavior	 negatively.74	 However,	 presence	 of	 regulation	 alone	 is	 not	 sufficient;	
effective	regulation	must	be	well	designed.	This	involves	an	appropriate	legislative	
mandate,	 a	 clear	 legal	 framework	 and	 a	 regulator	 in	 place	 to	 monitor	 and	
implement	regulation	that	is	properly	accountable.75	These	give	the	full	force	of	law	
to	the	regulatory	authorities	which	is	key	to	achieve	regulatory	objectives.		
39	
Are	there	regulations	in	place	to	ensure	appropriate	use	of	antimicrobials	
in	animal	health?			
40	
Is	there	an	authority	in	place	to	monitor	and	enforce	legislation,	if	so	
does	this	authority	have	a	dedicated	budget?	
14	-	Fostering	R&D	and	Facilitating	Market	Access	to	Novel	Products	
Whilst	 there	 were	 significant	 gains	 in	 antibiotic	 discovery	 between	 1940-1990,	
research	 and	 development	 (R&D)	 has	 shifted	 to	 other	 therapeutics	 due	 to	 a	
combination	of	economic,	regulatory,	and	scientific	barriers.76,77	A	comprehensive	
AMR	NAP	should	include	both	fostering	R&D	and	facilitating	market	access	to	novel	
products,78,79	 such	 as	 antimicrobials,	 diagnostics,	 vaccines	 and	 alternative	
treatments	such	as	probiotics,	metals	or	antimicrobial	peptides.80,81	To	foster	R&D,	
NAPs	can	include	the	use	of	financial	incentives	in	the	form	of	push	incentives	such	
as	 research	grants,	or	pull	 incentives	 such	as	monetary	 rewards,	 reimbursement	
premiums	or	patent	buy-outs	by	governments,82	to	fund	these	many	countries	have	
dedicated	budgets.83	To	maximise	allocative	efficiency,	financial	incentives	should	
also	 be	 linked	 to	 predefined	 public	 health	 needs	 and	 target	 product	 profiles.84	
Comprehensive	 R&D	 should	 also	 address	 preclinical	 scientific	 challenges	 in	
antimicrobial	development,	spanning	basic	drug	discovery	science	to	translational	
research	to	clinical	 trials.85	To	meet	 the	sometimes	conflicting	aims	of	 improving	
patient	 access	 and	 promoting	 stewardship,	 NAPs	 should	 consider	 alternative	
business	 model	 to	 facilitate	market	 access	 for	 novel	 antimicrobials.82	 Finally,	 to	
avoid	duplication	of	efforts	on	the	 international	 level,	and	given	that	research	of	
41	
Is	fostering	R&D	and	facilitating	market	access	to	novel	antimicrobials,	
diagnostics,	vaccines	and	alternative	treatments	in	both	human	and	
animal	health	listed	as	a	priority	in	NAP?	
42	
Does	the	NAP	consider	how	the	country	can	contribute	to	R&D	of	novel	
agents	at	both	a	national	and	international	level?		
43	
Is	there	a	dedicated	national	budget	for	R&D	of	novel	antimicrobials,	
diagnostics,	vaccines,	or	alternative	treatments?	
novel	 antimicrobials	 is	 not	 a	 viable	option	 for	 all	 countries,	 each	 country	 should	
identify	 potential	 areas	 of	 comparative	 advantage	 and	 seek	 to	 harmonize	 with	
international	efforts.		
	
AMR,	antimicrobial	resistance;	EU,	European	Union;	IPC,	infection	prevention	and	control;	NAP,	national	action	plan;	R&D,	research	and	development	 	
Table	5.	AMR	Governance	Framework,	Area	3	-	Monitoring	and	Evaluation	
	
3	-	Monitoring	and	Evaluation	
Domains	&	Indicators	 Key	Issues	
15	-	Reporting	
While	it	is	not	realistic	for	an	AMR	NAP	to	be	revised	on	an	annual	basis,	annual	
progress	reports	are	a	useful	mechanism	to	monitor	and	evaluate	AMR	policies	in	
the	interim.	These	progress	reports	can	also	be	used	by	other	countries	to	inform	
their	AMR	policies	and	provide	feedback	to	international	public	health	
bodies/agencies	on	national	achievements.	Annual	reports	on	data	collected	by	
national	AMR	surveillance	systems	can	improve	accountability	and	transparency,	
facilitate	regular	monitoring	and	evaluation	and	feed	into	AMR	NAP	progress	
reports.	It	is	also	an	important	aspect	of	national	governance	that	countries	
engage	with	wider	international	efforts	to	monitor	the	extent	of	AMR	globally.	
Therefore,	it	is	essential	that	national	surveillance	systems	collaborate	with	and	
relay	data	to	international	surveillance	systems.		
Indicator	
44	 Are	annual	AMR	NAP	progress	reports	published?	
45	
Are	annual	surveillance	reports	published	containing	data	regarding	the	
incidence	of	resistant	organisms	and	antimicrobial	use?	
46	
Is	there	collaboration	with	and	systematic	data	transmission	to	
international	surveillance	systems?	
16	-	Feedback	Mechanisms	
For	surveillance	to	be	an	effective	tool	for	improvement,	data	needs	to	be	routinely	
fed	back	at	regional	and	organizational	level.	In	practice,	this	implies	involving	local	
stakeholders	in	analysis	of	what	the	data	shows,	where	improvement	is	needed	and	
their	 specific	 data	 needs.	 To	 assess	 relative	 performance,	 these	 feedback	
mechanisms	 should	 also	 be	 aligned	with	 nationally	 set	 targets	 and	 deadlines	 as	
discussed	 in	 Domain	 1.	 If	 progress	 towards	 national	 targets	 is	 limited,	 local	
stakeholders	should	be	encouraged	to	produce	personalized	and	time-bound	action	
plans.	To	improve	accountability,	a	NAP	should	identify	deadlines	to	review	progress	
of	 specific	 actions,	 as	 well	 as	 arrangements	 to	 feedback	 at	 both	 regional	 and	
organization	level.		
47	
Are	there	feedback	mechanisms	in	place	which	relay	surveillance	data	
back	at	both	regional	and	organisational	level?	
48	
Are	there	regular	deadlines	in	place	to	review	progress	of	specific	actions	
within	the	NAP,	and	arrangements	to	feedback	at	both	regional	and	
organisation	level?	
	
17	-	Effectiveness	
Under	monitoring	and	evaluation,	methods	of	measuring	AMR	policy	effectiveness	
should	be	outlined	within	a	NAP,	and	if	possible	also	cost-effectiveness.	AMR	is	a	
driver	 of	 healthcare	 expenditure	 due	 to	 increased	 morbidity	 and	 mortality,	
likelihood	 for	 hospitalization,	 average	 hospital	 length	 of	 stay,	 cost	 of	 last-resort	
treatment	 options,	 and	 productivity	 losses	 for	 patients	 at	 work.86,87	 From	 a	
governance	perspective,	 it	 is	 important	to	establish	which	AMR	policies	are	cost-
effective	 and	 represent	 value-for-money.	 Sources	 of	 data	 could,	 for	 example,	
49	
Have	there	been	efforts	to	evaluate	the	effectiveness	(e.g.	measure	of	
impact	on	human	and	animal	health)	of	specific	policies	and/or	
interventions	implemented?	
50	
Have	there	been	efforts	to	evaluate	the	cost-effectiveness	(e.g.	measure	
of	impact	on	human	and	animal	health)	of	specific	policies	and/or	
interventions	implemented?	
include	surveillance	systems,	hospitals,	clinicians,	the	agricultural	sector,	and	food-
supply	chains.	Each	source	provides	feedback	on	the	impact	of	policies	in	reducing	
antimicrobial	 consumption,	 inappropriate	 use	 of	 antibiotics	 and	 antimicrobial	
resistance	rates.	Although,	estimating	the	effectiveness	and	cost-effectiveness	of	
individual	 interventions	 and/or	 policies	may	 be	 challenging	 as	many	 factors	 will	
contribute	 to	 an	 increase	 or	 decrease	 in	 antimicrobial	 use/AMR.	 Accordingly,	
technical	advisory	and	support	groups	should	be	involved	in	the	process,	and	cost-
effectiveness	 analysis	 should	 ideally	 result	 in	 a	 comparative	measure	 such	as	 an	
incremental	 cost-effective	 ratio	 (ICER),	 which	 can	 allow	 comparisons	 between	
interventions	to	rationalize	funding	decisions.	
18	-	AMR	Research	
‘Generation	 of	 information/intelligence’	 is	 a	 vital	 aspect	 of	 governance.	 In	 the	
context	of	national	AMR	policy,	a	national	research	strategy	is	required	to	provide	
an	evidence	base	for	AMR	policies.	Without	a	thorough	understanding	of	the	drivers	
of	 AMR	 and	 polices	 in	 place	 to	 limit	 them,	 resistance	 will	 develop	 to	 new	
antimicrobials.	 Research	 should	 also	 consider	 including	 modelling	 exercises	 to	
forecast	incidence	and	prevalence	of	AMR	as	well	as	the	current	and	future	health	
and	 economic	 impact.	 Priorities	within	 the	 national	 research	 strategy	 should	 be	
multidisciplinary	and	potentially	defined	by	an	intersectoral	committee	to	ensure	a	
One	Health	approach.	This	may	 include	 inputs	across	social	 sciences,	behavioral,	
economic,	 and	 medical	 research.88	 For	 the	 long-term	 sustainability	 of	 research	
activities,	it	is	important	to	put	in	place	a	dedicated	budget	at	the	national	level.	
52	
Is	research	to	understand	both	the	drivers	and	impact	of	AMR	as	well	as	
potential	policies	and	interventions	identified	as	a	key	priority	in	the	NAP?	
52	 Is	there	a	dedicated	national	budget	for	AMR	research	in	place?	
	
AMR,	antimicrobial	resistance;	ICER,	incremental	cost-effective	ratio;	NAP,	national	action	plan
Discussion	248	
Summary	of	question,	methods,	main	results	249	
A	central	challenge	to	combatting	the	global	threat	of	AMR	is	the	successful	implementation,	in	each	250	
country,	of	an	AMR	NAP	across	the	relevant	sectors	and	levels,	which	can	be	enabled	by	a	systematic	251	
approach	 to	 governance.	 Here,	 we	 have	 developed	 the	 first	 comprehensive	 framework	 for	 the	252	
governance	 of	 AMR	 NAPs	 by	 synthesising	 findings	 from	 a	 review	 of	 health	 system	 governance	253	
frameworks,	an	analysis	of	the	guidance	from	major	international	organizations,	and	extensive	input	254	
from	expert	policy-makers,	practitioners,	and	researchers	from	government	ministries,	 international	255	
organizations,	 policy	 institutes	 and	 academic	 institutions.	Within	 a	 cyclical	 design,	 our	 governance	256	
framework	consists	of	52	indicators	that	are	contained	within	18	domains	and	grouped	in	three	main	257	
governance	 areas:	 “policy	 design”,	 “implementation	 tools”,	 and	 “monitoring	 and	 evaluation”.	 It	 is	258	
intended	to	aid	policy-makers	to	design,	implement,	monitor,	and	evaluate	AMR	NAPs	across	the	‘One	259	
Health’	 spectrum,	as	well	as	 to	 facilitate	objective	assessments	of	countries’	AMR	NAPs	 to	 increase	260	
accountability	and	stimulate	debate.		261	
Strengths	262	
To	our	knowledge,	this	is	the	first	study	that	provides	a	comprehensive	systematic	synthesis	of	available	263	
evidence	on	the	governance	of	AMR	NAPs	by	including	information	from	a	systematic	review	of	health	264	
system	governance	frameworks,	international	guidance,	and	over	20	experts	from	various	international	265	
organizations,	government	ministries,	policy	institutes	and	academic	institutions.	The	AMR	governance	266	
framework	has	several	strengths.	A	central	and	recurring	input	by	experts	was	the	need	for	usability.	267	
By	including	52	indicators,	and	18	domains	the	framework	balances	the	right	mix	of	comprehensiveness	268	
and	 usability	 for	 policy-makers.	 This	 was	 confirmed	 by	 various	 experts	 in	 the	 fourth	 stage	 of	 the	269	
development	of	the	framework.	The	cyclical	design	of	the	framework	reflects	the	dynamic	nature	of	270	
the	AMR	issue	and	the	corresponding	need	to	be	responsive	and	adaptive,	but	also	ensure	that	the	271	
governance	of	AMR	NAPs	itself	develops	and	improves,	reflecting	the	realities	observed	and	lessons	272	
learned.		273	
Limitations	274	
The	AMR	governance	framework	also	has	various	limitations.	Our	review	of	health	system	governance	275	
frameworks	 prioritised	 systematic	 and	 non-systematic	 reviews,	 therefore	 it	 is	 possible	 that	 certain	276	
governance	frameworks	were	overlooked.	It	can	also	be	argued	that	our	AMR	governance	framework	277	
would	benefit	from	either	reviewing	a	larger	body	of	international	guidance	documents	or	consulting	a	278	
larger	 sample	 of	 experts.	 However,	 the	 documents	 reviewed	 represent	 the	 most	 recent	 guidance	279	
developed	by	five	major	international	organisations	involved	in	AMR	policy.	Furthermore,	the	expert	280	
sample	 was	 balanced	 between	 international	 organizations,	 policy	 institutes,	 government,	 and	281	
academia,	as	well	as	backgrounds	relevant	to	the	‘One	Health’	approach.		282	
We	did	not	use	a	structured	consensus	method	during	development	of	the	framework.89	Our	283	
objective	is	to	facilitate	international	debate	around	a	universally	accepted	approach	to	governance	in	284	
national	AMR	policy.	The	establishment	of	the	“One	Health	Global	Leadership	Group”	on	AMR	285	
recently	recommended	by	the	UN	IACG	on	AMR	is	one	potential	forum	to	develop	international	286	
consensus.15	Alternatively,	a	more	detailed	assessment	of	a	county’s	approach	to	governance	of	NAPs	287	
could	be	incorporated	into	pre-existing	initiatives	such	as	the	WHO	Joint	External	Evaluation	tool,90	or	288	
the	global	tripartite	database	on	country	progress.	289	
A	further	limitation	of	our	AMR	governance	framework	is	related	to	applicability.	A	thorough	objective	290	
application	of	 the	 framework	would	be	resource	 intensive	due	to	 the	broad	nature	of	data	sources	291	
which	would	need	to	be	reviewed,	as	well	as	challenges	with	data	availability	as	some	policy	documents	292	
or	decisions	may	not	be	publicly	accessible.	As	a	result,	several	interviews	with	multiple	stakeholders	293	
within	each	country	may	need	to	be	conducted.	This	partially	explains	why	current	efforts	to	assess	294	
AMR	NAPs	such	as	the	global	tripartite	database	on	country	progress	revolve	around	the	use	of	a	self-295	
assessment	questionnaire.7		296	
Conversely,	 it	 can	 also	 be	 argued	 that	 the	 52	 indicators	 and	 18	 domains	 only	 provide	 a	 superficial	297	
assessment	 in	 certain	 areas,	 and	 do	 not	 assess	 quality	 of	 governance	 adequately.	 For	 example,	 a	298	
country	may	offer	education	to	all	relevant	professionals	regarding	AMR,	but	it	may	be	of	poor	quality	299	
and	brief,	or	alternatively	a	public	awareness	campaign	may	be	in	place,	but	it	is	poorly	financed	with	a	300	
narrow	 focus.	 Cross-country	 comparisons	 utilising	 this	 governance	 framework	 should	 therefore	 be	301	
made	with	caution	as	there	are	possibilities	for	misleading	conclusions.	302	
Finally,	 the	 AMR	 governance	 framework	was	 developed	 based	 upon	 experience	 and	 guidance	 that	303	
applies	most	typically	to	high-to-middle	income	countries.	In	low	income	countries	with	less	resources,	304	
limited	 national	 surveillance	 and	 less	 developed	 healthcare	 systems,91,92	 the	 application	 of	 the	305	
framework	is	possibly	ambitious.	To	address	this,	we	extended	the	sample	size	of	experts	to	include	306	
perspectives	 from	 low-to-middle	 income	 countries	 (LMICs).	 The	 feedback	 was	 positive,	 and	 this	307	
resulted	in	only	minor	changes	to	the	framework.	It	was	felt	this	framework	was	still	relevant	to	lesser	308	
developed	plans,	such	as	those	in	some	LMICs,	as	the	cyclical	nature	of	this	framework	captures	how	309	
shortcomings	in	pre-existing	national	action	plans	can	be	improved	throughout	subsequent	iterations	310	
and	repeated	applications	of	the	framework.		311	
Conclusion		312	
Defining	and	assessing	governance	of	AMR	NAPs	remains	challenging.	Despite	certain	limitations,	this	313	
AMR	governance	framework	is	the	first	attempt	at	developing	a	tool	for	policy-makers	to	improve	the	314	
governance	of	AMR	NAPs,	as	well	as	to	facilitate	the	objective	assessment	of	countries’	NAPs	to	increase	315	
accountability	and	stimulate	debate.	316	
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